{"entity":{"id":"schrodinger","kind":"company","name":"Schrödinger","aka":["Schrodinger","Schrödinger, Inc."],"tldr":"Schrödinger sells software that uses physics to predict how a candidate drug molecule will fit its target, so chemists can test ideas on a computer before making them. It also used the software on medicines of its own, two of which are in early cancer trials.","summary":"Schrödinger, founded in 1990 and listed on Nasdaq as SDGR, develops a physics-based computational platform for designing drug molecules and materials, which it licenses to pharmaceutical and biotech companies and also uses for its own programmes and partnered work. Its two proprietary clinical programmes are in cancer. SGR-1505 is a MALT1 inhibitor in a phase 1 open-label dose-escalation trial in people with relapsed or refractory B-cell malignancies, after the FDA cleared its investigational new drug application in June 2022. SGR-3515 is a Wee1/Myt1 inhibitor whose application was cleared in April 2024; dosing in a phase 1 trial in advanced solid tumours began in July 2024, and the company's pipeline page names ovarian and uterine cancer as the rationale. A third oncology candidate, the CDC7 inhibitor SGR-2921, was discontinued in August 2025. In its quarterly report for the period to 30 June 2026 the company said that beyond completing the two phase 1 trials it does not intend to start further clinical trials or take its other proprietary preclinical programmes into the clinic on its own, and plans to seek partners for SGR-1505 and SGR-3515. Partnered programmes listed on its pipeline page include an HPK1 programme with Nimbus in solid tumours and a JAK2 programme with Lilly in oncology.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://www.schrodinger.com/"},{"label":"Pipeline","url":"https://www.schrodinger.com/pipeline/"},{"label":"Company history (founded 1990)","url":"https://www.schrodinger.com/company/about/"},{"label":"Form 10-Q for the quarter to 30 June 2026 (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097826000068/sdgr-20260630.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001490978"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma","ovarian","endometrial"],"sections":["drug-discovery","ai-computation","targeted-therapy"],"technologies":["ai-drug-design"],"targets":["wee1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 10-Q states that SGR-2921 was discontinued in August 2025 but does not give the reason in the passage read; the reason is not recorded here. The drugs SGR-1505 and SGR-3515 have no drug records in OnCo, and MALT1 has no target record, so they are named in the text only. Headquarters is the business address in the company's SEC filings."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.schrodinger.com/","ticker":"SDGR","founded":1990,"stage":"public","investors":[],"funding":[]},"route":"/companies/schrodinger/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"}],"target":[{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/"}]}}